Clinical Trial

PET Tau - Neurodegenerative Disease Imaging

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such as frontotemporal degeneration (FTD).
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2017-05-03; most recent amendment 2025-10-10.
Status change: Active, Not Recruiting → Recruiting 2020-12-11
Status change: Recruiting → Active, Not Recruiting 2020-03-23
Trial Details
NCT Number NCT03143374
Lead Sponsor University of Pennsylvania
Collaborators: Avid Radiopharmaceuticals
Conditions Neurodegenerative Disease
Enrollment 300 participants
Start Date 2016-08-23
Primary Completion 2030-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2025-10-15